Background. After portal vein ligation of 1 side of the liver, the other side regenerates at a slow rate. This slow growth may be accelerated to rapid growth by adding a transection between the 2 sides, i.e., performing portal vein ligation and parenchymal transection. We found that in patients undergoing portal vein ligation and parenchymal transection, portal vein hyperflow in the regenerating liver causes a significant reduction of arterial flow due to the hepatic arterial buffer response. We postulated that the reduction of arterial flow induces hypoxia in the regenerating liver and used a rat model to assess hypoxia and its impact on kinetic growth. Methods. A rat model of rapid (portal vein ligation and parenchymal transection) and slow regeneration (portal vein ligation) was established. Portal vein flow and pressure data were collected. Liver regeneration was assessed in rats using computed tomography, proliferation with Ki-67, and hypoxia with pimonidazole and HIF-1a staining.
Portal vein occlusion results in only a moderate amount of hypertrophy: 30-40% in 4-6 weeks. 3 In contrast, >50% hepatectomy is associated with a rapid and extensive regeneration with the degree of hypertrophy at 80-90% within 10 days. 4 It is interesting to note that, in contrast to partial hepatectomy, no tissue is removed during portal vein occlusion. The observation that the liver regenerates after redirection of portal flow alone has led to the hypothesis that changes in portal vein hemodynamics may be contributing signals for liver regeneration. 5 This hypothesis has raised renewed interest after a recent discovery: transection between the right and left lobes in addition to portal vein ligation (PVL + T) in humans, without any liver mass removal, accelerates slow regeneration induced by portal vein ligation (PVL) alone. 6 This manipulation induces extreme and rapid regeneration prior to resection and allows for extended liver resections after a week of waiting. The novel procedure in patients has been called "in-situ split hepatectomy" or "ALPPS" (Associating Liver Partition and Portal vein ligation for Staged hepatectomy), and it induces the same kinetic growth rate as partial hepatectomy (ie, rapid regeneration). 7 The observation has attracted considerable interest from liver surgeons because it allows in-situ liver regeneration of an unknown extent. 8 Also, adding simple tourniquet ligation of the parenchyma to contralateral PVL has been found to achieve the same kinetic growth rate as a more aggressive surgical procedure with transection between the lobes. 9 Due to the obliteration of collaterals and intrahepatic shunts by the added transection, a possible trigger for rapid regeneration in the PVL + T model may be the hyperflow in the portal vein (ie, more volume flow per volume unit of liver tissue), while experimental evidence is missing. 10, 11 In the presence of portal hyperflow, there has been longstanding evidence of a "buffer response" of the hepatic artery. 11 Upon increase of portal vein flow per volume of tissue, the hepatic artery flow decreases accordingly to allow constant total sinusoidal blood flow. Since the oxygenation of liver tissue depends largely on the hepatic artery, we hypothesized that PVL + T leads to hypoxia, which in turn may be a stimulus of accelerated regeneration in the growing liver. We used a rat model of PVL and PVL + T to test this hypothesis.
METHODS
Human studies. Approval to perform the surgical procedure of PVL + T, the first stage of ALPPS, in patients was obtained from the Ethics Committee of the Kanton of Zurich in the context of a prospective international registry (NCT01924741). Consents for collection of intra-and perioperative data were obtained from patients.
Portal vein ligation plus transection in human patients. PVL + T was performed at 2 hospitals (University Hospital Zurich and Kantonsspital Winterthur, Switzerland), as previously described. 12 Hemodynamic measurements in human patients. Portal vein flow was measured using 16-mm flow probes (Transonic, Ithaca, NY), and hepatic artery flow was measured using 4-mm flow probes, expressed in mL/min. Portal vein pressure was measured using Draeger Infinity Monitoring system (Draeger, L€ ubeck, Germany).
Animals. Approval for the experiments was obtained from the Veterinary Authorities of the Canton of Zurich, Switzerland (number 60/2014). All experiments with male Wistar rats (Charles River, Sulzfeld, Germany) were performed in compliance with the guidelines for Experiments on Animals by the Swiss Academy of Medical Sciences and the Federation of European Laboratory Animal Science Associations guidelines. To help condition them for the procedure, rats were kept in ventilated cages (4 rats each) under standard pathogen-free conditions in a 12/12-hour light/dark cycle for at least 5 days prior to the performance of the procedure. The ambient temperature was 22 ± 18C. Food and water were provided ad libitum. The median weight of the animals was 265 g (interquartile range [IQR] 250-295). We performed the volumetric studies by computed tomographic (CT) imaging in 5 rats per group. Likewise for tissue and blood samples, groups of 5 animals were killed at each time point. The exact number of animals per experiment (n) is indicated in the figures.
Anesthesia animals. During all operative procedures, animals were allowed to breathe spontaneously under isoflurane anesthesia (Attane, Piramal, Mumbai, India), 1.0-2.5 vol% vaporized in 600 mL oxygen/min. Analgesia was provided using a standard protocol of subcutaneous buprenorphine injections.
Model of slow and rapid liver regeneration after PVL in rats. To develop models of slow and rapid liver regeneration in rats, the right middle lobe (RML 25% of total liver volume) Fig 1, A was chosen as the liver remnant. Slow liver regeneration (PVL , Fig 1, A) of the RML was induced by ligating the portal vein of the right, the caudate, and the left lateral lobe using 6-0 silk ties (Fig 1) . Rapid regeneration (PVL+T , Fig 1, A) was induced by additionally transecting along the ischemic line with a nonsticking bipolar microforceps (Supergliss, Sutter GmbH, Freiburg i.B., Germany; PVL + T). Sham operations with loose, nonoccluding ligatures around the respective portal veins (sham operated, Fig 1, C) , and only transection between RML and left middle lobe (transection alone, Fig 2, C) were used as controls.
Application of dimethyloxalylglycine. Twelve hours before the operation dimethyloxalylglycine ([DMOG] Axxora Ltd, Nottingham, UK) was intraperitoneally administered (200 mg/g body weight). 13 To examine the incidentally discovered topical effect of DMOG on liver proliferation, we used a small paint brush to apply the DMOG solution onto livers.
Application of myo-inositol-trispyrophosphate. Myo-inositol-trispyrophosphate ([ITPP] Carbosynth, Compton, Berkshire, UK) was dissolved in normal saline (200 mg/mL) and administered by intraperitoneal injection of 0.3 mg/g of body weight each, 12 hours before the operation.
14 On the first postoperative day, 0.1 mg/g of body weight was again applied.
Hemodynamic measurements in rats. To assess portal flow, 2-mm flow probes (Transonic, Ithaca, NY) were used. Volume flow probes measure volume directly rather than extrapolating from flow velocity and vessel diameter. Portal vein pressure was determined using pressure transducers and anesthesia monitors (Dr€ ager, L€ ubeck, Germany).
Volumetry of rat livers. To assess regeneration of the RML, animals underwent repetitive CT and volumetry scanning every 24 hours for up to 72 hours (Quantum FX MicroCT, PerkinElmer, Waltham, MA) after prior intravenous injection of 200 mL of the contrast ExiTron nano 12,000 (Miltenyi Biotech, Bergisch Gladbach, Germany).
Pimonidazole staining to quantify tissue oxygenation. Pimonidazole was dissolved in normal saline (100 mg/mL), and 60 mg were injected intravenously 1 hour prior to harvesting the organs. 15 Pimonidazole undergoes chemical reduction under hypoxic conditions, binds irreversibly to SH-containing molecules, such as glutathione and proteins, and the resulting complexes accumulate in hypoxic tissue. The pimonidazole bound in tissue was visualized with monoclonal antibodies using immunofluorescence.
Histochemistry and immunofluorescence. Cryosections of 6 mm were fixed using acetone (Sigma Aldrich, St. Louis, MO) for pimonidazole staining or paraformaldehyde 4% (Sigma Aldrich) for 10 minutes at room temperature for Ki-67 staining. After 10 minutes, slides were kept in ice-cold phosphate-buffered saline (PBS, Kantonsapotheke Zurich, Switzerland) before the individual protocols were started. Slides were washed 3 times for 5 minutes; then, they were blocked at room temperature for at least 1 hour using 10% goat serum (Sigma-Aldrich) with 1% bovine serum albumin for pimonidazole staining or with 1 3 PBS+5% goat serum + 0.3% Triton X-100 for Ki-67 staining. Incubation with the primary antibody took place at 48C overnight. The following day a staining with an appropriate fluorochromecoupled secondary antibody took place for 2 hours at room temperature; nuclei were stained using 4,6-diamidin-2-phenylindol (DAPI, Roche, Rotkreuz, Zug, Switzerland).
For staining of hypoxia-inducible factor-1a (HIF1a), formalin-fixed, paraffin-embedded liver tissue was cut into 5 mm sections and placed on glass slides. Sections were deparaffinized with xylene, dehydrated with ethanol, and then incubated with 3% hydrogen peroxide to block endogenous peroxidase. Antigen retrieval was performed by heating in 10 mM sodium citrate buffer (pH 6.0). Sections were blocked in DAKO protein block (X9090; DAKO, Glostrup, Denmark), followed by incubation with primary antibodies, rabbit anti-HIF-1a (Abcam 2185, diluted 1:800; Cambridge, UK); secondary antibodies were used to visualize target proteins. DAB reagent (K3466; DAKO) was applied in the detection procedure. Tissue sections were counterstained with Aqua Hematoxylin-INNOVEX (Innovex Biosciences, Richmond, CA). Negative controls included liver specimens exposed to 1% bovine serum albumin instead of to the respective primary antibodies. The number of detected HIF1a immunoreactive cells was quantified by counting in 20-40 randomly chosen, 203 fields per section per animal.
The following primary antibodies were used: rabbit anti-Ki-67 (Abcam, diluted 1:400) and rabbit anti-pimonidazole (Hypoxyprobe, MA; diluted 1:200). Slides were mounted with ProLong Gold Antifade Mountant (Life Technologies, Zug, Switzerland).
Image acquisition and processing. Immunofluorescence images were acquired with the Slidescanner Axio Scan.Z1 (Zeiss, Feldbach, Zurich, Switzerland) and the ZEN blue (Zeiss) imageprocessing and analyzing software. A 203 objective with aperture was used; the maximal intensity was set to 5,247.
Determination of mean fluorescence intensity in pimonidazole-stained liver slices. Image analysis was performed using R: a language and environment for statistical computing 16 and the EBImage, an R package for imaging processing with applications to cellular phenotypes (R Foundation for Statistical Computing, Vienna, Austria). 17 Briefly, variance in fluorescence intensity of liver slices was expressed in relation to positive control (hepatic artery ligation, mean variance = 100%) and negative control (sham surgery, mean variance = 0%). The R code of this procedure is included in the online only Data supplement.
Generation of a fusion image based on DAPIand Ki-67-stained liver slices and quantification of Ki-67-positive cells. Red, green, blue (RGB) fusion images from DAPI-and Ki-67-stained liver slices were computed using R 16 and the EBImage package. 17 Matching DAPI-and Ki-67-stained fluorescence spots were also highlighted as red spots using the "paintObjects" function. The R code of this procedure is enclosed in the online only Data supplement. The number of Ki-67 positive cells was determined by evaluation of 5 random visual fields at 2003 magnification.
Experimental outcomes and statistical methods. The primary outcome was liver hypertrophy measured volumetrically in 24-hour intervals after PVL and PVL + T. Secondary outcomes were proliferation as assessed by KI-67 staining. Data are means and standard deviations (SDs) for normally distributed data, median, and IQR for skewed data. For comparisons of normally distributed groups, we used the Student t test (2 groups) or analysis of variance ([ANOVA] for >2 groups) with Sidak-correction for multiple comparisons. Details on the statistical analysis used for each experiment are given in legends to Figs 2-6. Prism 6.0 (GraphPad Software Inc, San Diego, CA) was used for data analysis and presentation.
RESULTS
Right middle lobe serves as the regenerating lobe in the rat model. The rat liver consists of right, middle, left lateral, and caudate lobes (Fig 1, A) . Small animal CT with intravenously applied contrast injection allowed assessment of the volumes of each lobe in an exact manner (Fig 1, B) . The only lobe in rodents that has inflow from 2 separate portal veins and may serve as a model for selective portal vein ligation, with or without transection, is the middle lobe. We used the RML as the regenerating lobe, because the portal vein to the RML can be ligated easily, while ligation of the portal vein to the LML requires resection of the left lateral lobe and thereby a mass reduction of the liver, which we tried to avoid. The RML had a volume of 2.4 ± 0.5 mL or 26% of the total liver in rats with a median weight of 265 g. In humans, a remnant volume of <30% generally requires a procedure to increase the remnant volume before resection.
3 Figure 1 , C shows the types of portal vein occlusion procedures performed to induce slow regeneration with PVL and rapid regeneration with PVL + T.
Transection between lobes accelerates regeneration in the rat model. Representative CT scans performed every 24 hours to assess the volume increase of the RML are shown in Fig 2, A. Fine lines drawn around the regenerating lobe to measure volume without sacrificing the animals are highlighted (Fig 2, A) . PVL and PVL + T resulted in a significant volume increase within 24 hours after the operation of 44% and 74%, respectively, while the sham-operated group showed no change in liver volume (Fig 2, B) . After 72 hours of continuous growth, the relative volume increase of PVL and PVL + T was 104% and 147% of the starting volume, respectively; sham-operated animals did not show significant changes in liver volume. PVL + T led to a significantly higher volume increase when compared with ligation alone.
The fraction of Ki-67 positive cells was evaluated using immunofluorescence with evaluation of fluorescence signal in a slide scanner and digital enlargement of positive signals at 3, 12, 24, and 72 hours (Fig 2, C) . The proliferation rate of PVL and PVL + T was significantly higher compared with sham animals at 3, 24, and 72 hours, but interestingly not at 12 hours (Fig 2, D) . Proliferation was significantly increased in PVL + T at 3, 24, and 72 hours when compared with PVL. There was no difference at 12 hours between the 2 groups. The histologic proliferation data confirmed the findings of volume increase by CT in the rapid and the slow regeneration model and shows that the degree of Ki-67 staining correlates well with volumetrically measured liver growth, except for the 12 hour time point.
Portal vein ligation induces portal hyperflow in the regenerating liver in both the rapid and slow regeneration models. Flow in the main portal vein in 15 human patients before and after PVL + T, the first step of the so-called "ALPPS" operation in humans as reported elsewhere, 6 ,12 was 704 ± 210 mL/min at baseline. Flow did not change immediately after ligation and transection or 7 days later (Fig 3, A1) . Given that 70-80% of the portal vein flow outflow is occluded in PVL + T, no reduction in prehepatic hepato-petal In patients, hepatic artery flow decreases in the left hepatic artery to the regenerating lobe from 116 ± 8 to 71 ± 70 mL/min (##P = .014, n = 15), reflecting the buffer response of the hepatic artery to portal hyperflow. In contrast, it increases in the right hepatic artery to the deportalized lobe from 227 ± 80 to 446 ± 190 mL/min (#P = .001, n = 15) to buffer the lack of portal blood flow. Data are given as single data points, depending on normality, as mean ± standard deviation or medians ± IQR. ANOVA (human data, n = 15) or Kruskal-Wallis test (rat data, n = 4) were performed for comparisons of groups.
volume flow in the main portal vein is indirect proof of more flow per remnant liver volume (20-30%) perfused (ie, "portal hyperflow"). Similarly in rats, volume flow in the main portal vein did not change from a baseline of 15 mL/min (12-16 mL/min), neither after 75% portal vein ligation and thereby flow space removal in PVL (Fig 3, A2) , nor after PVL + T (Fig 3, A3) . Portal vein pressures in humans undergoing PVL + T increased significantly from 12 ± 5 mm Hg prior to the procedure to 18 ± 4 mm Hg after ligation and transection and stayed elevated for 7 days (Fig 3, B1) . Similarly in rats, portal vein pressures in the main portal vein undergoing PVL (Fig 3,  B2) and PVL + T (Fig 3, B3) increased significantly after the portal vein ligation step. However, the added transection in PVL + T did not increase the pressure further (Fig 3, B3) . Pressure remained elevated at 3, 12, and 24 hours in both the PVL and PVL + T groups.
Reduced arterial flow in PVL + T in patients. We measured arterial flow in the human liver remnant before and after the first stage of the "ALPPS" operation in humans. Flow in the left hepatic artery decreased significantly from 116 ± 80 mL/min at baseline to 71 ± 70 mL/min after PVL + T, likely an adaptation to the portal hyperflow, known as the hepatic arterial buffer response 10, 18 (Fig 3,  C1) . This decrease in arterial flow remained unchanged for up to 7 days. The flow in right hepatic artery to the deportalized lobe after PVL + T increased from a baseline of 227 ± 80 mL/min to 446 ± 190 mL/min (Fig 3, C1) . This upregulation in flow also may be explained by the hepatic arterial buffer response and remains unchanged for up to 7 days after the operation.
Pimonidazole staining demonstrates local tissue hypoxia in rapid regeneration. To identify hypoxic areas in the regenerating liver, pimonidazole was used as a well-known marker for detection of hypoxic tissues. 19 Immunohistochemistry showed no specific signal in sham-operated animals (Fig 4, A) . Upon hepatic artery ligation in rats (positive control), staining in the zone around the central vein was found (Fig 4, B) . No specific signal was identified in regenerating hepatic tissue after PVL (Fig 4, C) . However, there was intense staining after PVL + T (Fig 4, D) . We used immunofluorescence-stained slides for quantification (Fig 4, E) based on an algorithm to assess the contrast between specific and nonspecific staining (online only Data supplement). In this algorithm, the variance in pixel intensity of liver tissue was assessed. Relative values were calculated by setting the mean variance of liver slices after sham surgery at 0%, while the mean variance of all liver slices after hepatic artery ligation was set at 100% (Fig 4, E) . While there was no difference between PVL and sham-operated animals, PVL + T showed significant hypoxia, comparable to hepatic artery ligation, in the regenerating liver lobe at 3 and 12 hours (Fig 4, F) . HIF-1a expression quantified by immunohistochemistry was higher in PVL + T when compared with PVL alone (Fig 4, G) .
Rapid regeneration can be induced in the slow regeneration model by activation of hypoxic signaling pathways. Prolyl hydroxylase domain (PHD) 1-3 oxygen-sensing enzymes are natural gatekeepers of the adaptive response to hypoxia. 20 Under normoxia, PHD are constantly marking the continuously transcribed and translated HIF-1a subunits for degradation, while in hypoxia, the substrate for hydroxylation is missing. As a consequence, HIF-1a is upregulated and activates numerous hypoxic signaling pathways. With the hypothesis of pharmacologically changing slow to rapid liver regeneration, the PHD inhibitor DMOG was given to animals prior to PVL (slow regeneration). This intervention led to an enlargement of the RML volume from a baseline of 2.5 ± 0.5 mL to a final volume 6.6 ± 0.4 mL at 72 hours with increases of 60 ± 14% at 24 hours, 88 ± 11% at 48 hours, and 134 ± 21% at 72 hours (Fig 5, A) . This degree of volume increase was not different at any time point from PVL + T, and was significantly higher than the volume increases observed after PVL. Intraperitoneal injection of DMOG in rats undergoing sham surgery as a control led to no change in starting volume. DMOG in PVL also led to an increase in the proportion of Ki-67 positive cells (Fig 5, B) . The mitotic activity after PVL + DMOG was even higher than after PVL + T (P = .023; Fig 5, C) . There was no significant difference in the proportion of Ki-67 positive cells between sham-operated animals and sham-operated animals receiving DMOG prior to the operation. While DMOG given systemically before sham operation seemed to have no significant overall proliferative impact on liver tissue, when DMOG was applied locally to the surface of liver tissue, geographic areas of hypertrophy were visible on the liver surface (Fig 5, D) . Ki-67 staining showed 1-mm-deep areas of high proliferation (Fig 5, E) compared with areas from control animals that appeared macroscopically normal (P < .001; Fig 5, F) .
Reversing hypoxia by increasing oxygen delivery to the regenerating liver blunts rapid liver regeneration. ITPP is an allosteric effector of hemoglobin and enhances the capacity of hemoglobin to release oxygen in tissue. 21 It is well known that this compound substantially abrogates hypoxia in tumors, leading to reduced tumor growth.
22, 23 We therefore tested to see if rapid regeneration could be abrogated by increasing oxygen delivery to the growing liver by treating the group of animals undergoing PVL + T. When given 12 hours before and at the first day after the operation, ITPP clearly reduced liver regeneration after PVL + T. Right median lobe volume changed from a baseline volume of 2.3 ± 0.2 mL to only 4.8 ± 0.6 mL at 72 hours (P < .001), a reduced volume increase over time (Fig 6, A) . This volumetric growth was not different at any time point from growth after PVL, but significantly decreased compared with the volume increase observed after PVL + T. Intraperitoneal injection of ITPP in rats undergoing sham surgery led to no change in volumetry volume.
Application of ITPP prior to PVL + T led to less Ki-67 positive cells compared with PVL + T at 72 hours (Fig 6, B) . The degree of mitotic activity in PVL + T plus ITPP was decreased significantly and not different from PVL (Fig 6, C) . There was no significant difference in the proportion of 
DISCUSSION
This study provides first evidence that hypoxia modulates the kinetic rate of liver regeneration. Our finding of hypoxia in liver remnants undergoing rapid liver regeneration was supported by the transformation of slow regeneration into rapid regeneration using a PHD inhibitor. In contrast, increase in oxygen delivery to the rapidly regenerating lobe using ITPP abrogated rapid regeneration and reduced it to the slow liver regeneration found after PVL. Importantly, the PHD inhibitor DMOG additionally triggered de-novo regeneration of 1 mm depth upon local application to rat livers without any portal vein manipulation. This group of drugs is currently in clinical phase III trials for applications unrelated to liver regeneration and will have to be evaluated as a therapeutic agent for drug-inducible liver regeneration. (see schematic Fig 7) Based on our findings, hypoxia may be the rate determining mechanism for rapid regeneration after PVL + T. While there is no hypoxia present in the slowly regenerating liver after PVL, the regenerating lobe after PVL + T seems profoundly hypoxic as shown by pimonidazole staining. This degree of hypoxia may be explained by the reduction of oxygen-rich arterial flow in the regenerating liver lobe in PVL + T as assessed in our arterial flow studies in humans. In contrast, this mechanism may have little or no importance when there is compensatory blood flow between liver lobes through sinusoidal collaterals such as in PVL. Interestingly, reduced arterial flow has been demonstrated repeatedly in regenerating livers in animal models of partial hepatectomy, [24] [25] [26] smallfor-size live donor liver transplantation 25, 27 and in models of liver regeneration after PVL, 10 but its role as the accelerator of liver regeneration has so far not been understood.
In the rat model of PVL, we were not able to measure arterial flow to the regenerating lobe directly due to technical limitations, namely the unavailability of very small-volume flow probes.
However, the precise physiological measurements by Rocheleau et al, 10 using radiolabeled microspheres, demonstrated that in the rat liver with portal hyperflow arterial flow is reduced from 1 mL/min to 0.5 mL/min. Interestingly, we also observed about 50% reduction in arterial flow in our human flow measurements. In the study by Rocheleau et al, 10 the liver with arterial flow grew in size. The authors also demonstrated a correlation between decreasing arterial flow in the regenerating lobe and increasing portal flow. Essential to keeping portal flow constant, hepatic arterial autoregulation was first described as the "hepatic arterial buffer response" 11 and was explained by the differential washout of adenosine with different degrees of portal flow. 18 Interestingly, based on this physiological effect, hypoxia has been postulated repeatedly to "accompany" liver regeneration. 5, 10 In stark contrast to our findings, hypoxia has been viewed by most as detrimental to liver regeneration, 28 and abrogating hypoxia through surgical maneuvers, like portal vein arterialization, has been considered beneficial to the regenerating liver. 25 Recently, investigators described the presence of the master regulator of hypoxia HIF-1a in regenerating livers after resection, 29, 30 not just in response to hypoxic injury but as an important regulator of hepatic metabolism in general. 31, 32 It also has been demonstrated that liver regeneration is actually increased in mice deficient for PHD-1 and that increased HIF-1a activity in the regenerating liver not only induced a protective response, but also accelerated liver regeneration. 33 We actually speculated that hypoxia sensing might be used therapeutically in extended liver resections and liver transplantation, and our study supports these ideas. Our finding of differential degrees of liver regeneration after portal vein manipulation and the pro-mitotic effect of the local application of a PHD inhibitor allowed us to show that hypoxia sensing not only enhances liver regeneration, but also may serve as an initiator of liver regeneration independently of portal hyperflow.
Very recently, the powerful effect of stabilization of HIF-1a, and thereby hypoxia sensing on regenerative processes, has been pointed out in a model of epidermal wound healing. 34 It was shown that the PHD inhibitor 1,4-dihydrophenonthrolin-4-one-3-carboxylic acid used in a local gel application in B6 mice in the ear punch hole model leads to accelerated wound healing via the dedifferentiation and mobilization of progenitor cells. We speculate that similar processes of cell reprogramming to glycolytic progenitor cells in the liver and further generation of hepatocytes from progenitor cells may be initiated and controlled by arterial flow restriction in the regenerating liver, inducing hypoxia-signaling pathways. Which cells constitute these progenitor cells remains unclear. Using Ki-67 staining, we observed 2 peaks of proliferation: 1 immediately after the procedure at 3 hours, followed by a decrease in proliferative activity at 12 hours and then an increase at 24 hours. It is well known that 2 stages of liver regeneration occur. [35] [36] [37] The first consists of the activation of signaling pathways, including growth factors, cytokines, neuroendocrine factors, and paracrine signals (called priming phase), peaking between 2-3 hours after the operation. It is followed by a second proliferative phase with hepatocyte DNA synthesis, 37 with maximum activity between 24 and 48 hours. While in our study regeneration activity in the liver with PVL seems to be absent in the priming phase at 3 hours, there is proliferation in the PVL + T at this very early stage. PVL + T may accentuate the priming phase of regeneration. Additional study will help us learn why this early proliferation occurs. Hypoxia in PVL + T may induce early cell proliferation. Through transection, collateral flow between RML and LML is interrupted completely, which further increases the concentration of growth and inflammatory mediators in the RML, possibly accentuating and accelerating regeneration processes.
Several groups have presented animal models of the PVL + T procedure. 38, 39 One study in rats demonstrated accelerated hypertrophy of the RML after PVL + T, the same model we used. The authors hypothesized that interruption of vascular shunts between the deportalized and the regenerating liver may explain rapid hypertrophy in PVL + T, 38 but they did not assess the hemodynamic effects of the operation. They speculated that the increased growth rate of PCL + T may be explained by hepatocellular damage and necrotic areas in the deportalized LML via an increased expression pattern of inflammatory mediators, like IL-6 and TNF-a. Another study examined PVL + T, but the authors did not really use a model of rapid hypertrophy without mass reduction. They combined liver resection of the left lateral lobe with PVL + T, and thereby created a partial liver resection and portal vein occlusion model at the same time. Their study suggested that rapid hypertrophy was purely a result of systemic trauma induced by the transection of the liver and also could be induced by operative damage to the spleen and lungs. 39 However, in our study, PVL combined with tourniquet instead of transection also induced an acceleration of volumetric growth similar to reports in patients undergoing PVL with tourniquet ligation instead of transection. 9 Therefore, our study supports the concept that abrogation of collateral flow, rather than the trauma caused by transection alone, plays the key role in modulating regenerative kinetics.
Flow and pressure measurements in patients undergoing PVL + T as a liver resection strategy revealed that flow volume in the main portal vein did not change after PVL + T. However, an increase in portal vein pressure was observed. These findings were confirmed in our rat model. Given these findings, we conclude that portal hyperflow, arithmetically 4 times the flow per tissue unit, results in increased portal vein pressures in PVL as well as PVL + T. We further investigated the hepatic arterial buffer response in the regenerating liver. Flow measurement in humans showed that the hepatic arterial flow to the regenerating liver was decreased significantly in PVL + T. The observation that transaminases are significantly higher after PVL + T than they are after PVL alone, in our experience and in both experimental articles on PVL + T, 38, 39 may be explained by hypoxic cell death rather than by the trauma of transection.
Because we were unable to measure rat arterial volume flow, we chose to induce hypoxia sensing by activating HIF-1a pathway in the regenerating lobe after PVL using the well-established PHD inhibitor DMOG. We hypothesized that this might increase the regenerative rate in the same way that adding a transection between the lobes would. DMOG given to rats undergoing PVL induced a similar acceleration of regeneration as performing a transection between the regenerating and the deportalized lobe. Interestingly, we observed that the local application of DMOG to rat livers also induced a 1-mm deep area of liver regeneration of hepatic tissue without any portal vein manipulation. While augmentation of liver regeneration has been reported after partial hepatectomy in PHD-1 knockout mice, 33 a triggering role for regeneration without liver resection has so far not been described.
DMOG, however, may influence other pathways beyond HIF-1a subunit stabilization. To demonstrate that hypoxia sensing is the catalyst of rapid hypertrophy, we needed to confirm that increase of tissue oxygen abrogates rapid hypertrophy and switches the rapid to the slow regeneration. We therefore used ITPP as an allosteric hemoglobin regulator to increase oxygen delivery to liver tissue. Rapid hypertrophy with the high mitotic rate was blunted substantially.
In conclusion, this study includes patient and animal data to provide the first evidence that hemodynamic changes and resulting hypoxia may explain rapid liver regeneration. It also points out the possible potential of PHD inhibitors to accelerate the slow regeneration associated with portal vein occlusion. Pharmacologic simulation of hypoxia may offer clinical advantages and may replace the surgical practice of PVL + T in the form of "ALPPS," an operation that, while opening new surgical options, has been proven to be fraught with complications and a prohibitively high mortality rate. 40, 41 We acknowledge the contribution of Tobias Piegeler, MD to the collection of data for the animal experiment and to the drafting of the first version of this paper.
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